Animal models of major depressive disorder and the implications for drug discovery and development
Demin K. A., Sysoev M., Chernysh M. V., Savva A. K., Koshiba M., Wappler-Guzzetta E. A., Song C., De A. M. S., Leonard B., Parker M. O., Harvey B. H., Tian L., Vasar E., Strekalova T. V., Amstislavskaya T. G., Volgin A. D., Alpyshov E. T., Wang D., Kalueff A. V.
Expert Opinion on Drug Discovery
Vol.14, Issue4, P. 365-378
Опубликовано: 2019
Тип ресурса: Обзор
DOI:10.1080/17460441.2019.1575360
Аннотация:
Introduction: Depression is a highly debilitating psychiatric disorder that affects the global population and causes severe disabilities and suicide. Depression pathogenesis remains poorly understood, and the disorder is often treatment-resistant and recurrent, necessitating the development of novel therapies, models and concepts in this field. Areas covered: Animal models are indispensable for translational biological psychiatry, and markedly advance the study of depression. Novel approaches continuously emerge that may help untangle the disorder heterogeneity and unclear categories of disease classification systems. Some of these approaches include widening the spectrum of model species used for translational research, using a broader range of test paradigms, exploring new pathogenic pathways and biomarkers, and focusing more closely on processes beyond neural cells (e.g. glial, inflammatory and metabolic deficits). Expert opinion: Dividing the core symptoms into easily translatable,
Ключевые слова:
animal modeling; Depression; endophenotype; major depressive disorder; pathogenesis
animal model; drug development; human; major depression; nonhuman; pathogenesis; priority journal; Review; animal; disease model; drug development; major depression; pathophysiology; procedures; translational research; antidepressant agent; Animals; Antidepressive Agents; Depressive Disorder, Major; Disease Models, Animal; Drug Development; Drug Discovery; Humans; Translational Medical Research
Язык текста: Английский
ISSN: 1746-045X
Demin K. A.
Sysoev M.
Chernysh M. V.
Savva A. K.
Koshiba M.
Wappler-Guzzetta E. A.
Song C.
De A. M. S. Abreu M.S.
Leonard B.
Parker M. O.
Harvey B. H.
Tian L.
Vasar E.
Strekalova T. V. Tat`yana Valeryevna 1969-
Amstislavskaya T. G.
Volgin A. D.
Alpyshov E. T.
Wang D.
Kalueff A. V.
Демин К. А.
Сyсоев М.
Чернyш М. В.
Савва А. К.
Кошиба М.
Wапплер-Гуззетта Е. А.
Сонг C.
Де А. М. С. Абреу М.С.
Леонард Б.
Паркер М. О.
Харвеy Б. Х.
Тиан Л.
Васар Е.
Стрекалова Т. В. Татьяна Валерьевна 1969-
Амстиславскайа Т. Г.
Волгин А. Д.
Алпyшов Е. Т.
Wанг Д.
Калуефф А. В.
Animal models of major depressive disorder and the implications for drug discovery and development
Текст визуальный непосредственный
Expert Opinion on Drug Discovery
Ashley Publications Ltd.
Vol.14, Issue4 P. 365-378
2019
Обзор
animal modeling Depression endophenotype major depressive disorder pathogenesis
animal model drug development human major depression nonhuman pathogenesis priority journal Review animal disease model drug development major depression pathophysiology procedures translational research antidepressant agent Animals Antidepressive Agents Depressive Disorder, Major Disease Models, Animal Drug Development Drug Discovery Humans Translational Medical Research
Introduction: Depression is a highly debilitating psychiatric disorder that affects the global population and causes severe disabilities and suicide. Depression pathogenesis remains poorly understood, and the disorder is often treatment-resistant and recurrent, necessitating the development of novel therapies, models and concepts in this field. Areas covered: Animal models are indispensable for translational biological psychiatry, and markedly advance the study of depression. Novel approaches continuously emerge that may help untangle the disorder heterogeneity and unclear categories of disease classification systems. Some of these approaches include widening the spectrum of model species used for translational research, using a broader range of test paradigms, exploring new pathogenic pathways and biomarkers, and focusing more closely on processes beyond neural cells (e.g. glial, inflammatory and metabolic deficits). Expert opinion: Dividing the core symptoms into easily translatable,